Hennion & Walsh Asset Management Inc. Has $1.32 Million Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Hennion & Walsh Asset Management Inc. boosted its holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 18.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 162,909 shares of the company’s stock after purchasing an additional 24,947 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.23% of ORIC Pharmaceuticals worth $1,315,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Creative Planning bought a new position in shares of ORIC Pharmaceuticals during the 3rd quarter worth approximately $116,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of ORIC Pharmaceuticals in the third quarter worth $132,000. China Universal Asset Management Co. Ltd. grew its stake in ORIC Pharmaceuticals by 71.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock valued at $139,000 after acquiring an additional 5,646 shares in the last quarter. XTX Topco Ltd bought a new stake in ORIC Pharmaceuticals during the second quarter valued at $153,000. Finally, Profund Advisors LLC boosted its position in shares of ORIC Pharmaceuticals by 23.6% during the 2nd quarter. Profund Advisors LLC now owns 21,861 shares of the company’s stock valued at $155,000 after acquiring an additional 4,175 shares during the last quarter. 95.05% of the stock is owned by institutional investors.

Insider Buying and Selling at ORIC Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 8,851 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $73,286.28. Following the completion of the sale, the chief financial officer now directly owns 106,764 shares of the company’s stock, valued at approximately $884,005.92. This represents a 7.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jacob Chacko sold 24,660 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $8.28, for a total value of $204,184.80. Following the completion of the transaction, the chief executive officer now owns 778,648 shares in the company, valued at $6,447,205.44. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 42,361 shares of company stock valued at $350,749. Insiders own 5.55% of the company’s stock.

ORIC Pharmaceuticals Price Performance

Shares of NASDAQ:ORIC opened at $9.58 on Friday. ORIC Pharmaceuticals, Inc. has a 1 year low of $6.33 and a 1 year high of $16.65. The stock’s fifty day moving average price is $9.00 and its 200-day moving average price is $9.49. The company has a market cap of $676.06 million, a P/E ratio of -5.32 and a beta of 1.18.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.01). On average, sell-side analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.84 earnings per share for the current year.

Wall Street Analyst Weigh In

ORIC has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Monday, January 13th. Wells Fargo & Company assumed coverage on shares of ORIC Pharmaceuticals in a report on Thursday, October 31st. They issued an “overweight” rating and a $20.00 price objective for the company. Finally, Wedbush restated an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday, January 13th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, ORIC Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $18.29.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.